Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty - A randomized Controlled Trial

详细信息    查看全文

• 作者：Naomi Kobayashi ; MD ; PhD ; Yutaka Inaba ; Makoto Uchiyama ; Hiroyuki Ike ; So Kubota ; Tomoyuki Saito
• 关键词：bone mineral density ; total hip arthroplasty ; teriparatide ; alendronate ; dual-energy x-ray absorptiometry
• 刊名：The Journal of Arthroplasty
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：31
• 期：1
• 页码：333-338
• 全文大小：739 K

文摘

In this study, the effect of teriparatide for the prevention of bone mineral density (BMD) loss after THA was compared with alendronate in a randomized controlled trial. Forty-eight patients were assigned to three groups, namely, the teriparatide, alendronate, and no medication groups. Dual-energy x-ray absorptiometry (DEXA) was performed at 1 week post-surgery as a baseline reference, followed by subsequent measurements at 12, 24, and 48 weeks postoperatively. For periprosthetic BMD loss, a significant effect of teriparatide was demonstrated, though its effect was similar to alendronate. On the other hand, higher lumbar BMD was observed in the teriparatide group than in the alendronate group at 48 weeks post-surgery. Teriparatide administration may be one reasonable option for osteoporotic patient to preserve the periprosthetic BMD after THA.